trending Market Intelligence /marketintelligence/en/news-insights/trending/torziwd5yotzmmhin7kynw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

RedHill Biopharma inflammatory drug meets goals of late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


RedHill Biopharma inflammatory drug meets goals of late-stage study

RedHill Biopharma Ltd. said the phase 3 study of its drug RHB-104 in an inflammatory bowel disease met its main and secondary goals.

Results from the study showed that RHB-104 was better than placebo in achieving remission, or reducing the symptoms, in people with Crohn's disease. At week 26, patients in the RHB-104 group achieved 37% remission, compared with 23% remission in the placebo group.

Statistically significant results also showed that patients who received RHB-104 had a greater response to the experimental treatment at week 26 compared with people in the placebo arm. Patients in the RHB-104 group, when compared with those who received placebo, also achieved higher rates of early remission at week 16 and continuous remission over weeks 16 to 52.

RHB-104 was found to be generally safe and well-received. Both treatment groups experienced similarly low rates of serious side effects and drug discontinuation due to treatment.

The Tel Aviv, Israel-based specialty biopharmaceutical company will continue to explore other goals of the study as additional data becomes available in the coming months.

"We continue to analyze the study data and plan to meet with key opinion leaders and the U.S. Food and Drug Administration to present the data package and discuss the development path to potential approval of RHB-104," Ira Kalfus, RedHill's medical director, said in the company's July 30 press release.

As of 2017, about 1.5 million people worldwide were diagnosed with Crohn's disease, according to the company. Global sales of Crohn's disease therapies are estimated to exceed $10 billion in 2018.

After an early surge, Redhill Biopharma's shares closed down 7.21% to $8.75 at 4 p.m. ET.